PDX1 and pachyonychia congenita: GEMMs that harbor KrasG12D, Trp53R172H and Pdx-1Cre (known as KPC) recapitulated the pathological and metastatic characteristics of human PC and are widely used in preclinical trials [8, 12, 13]; GEMMs that harbor Pdx1-Cre, LSL-KrasG12Dand Ink4a/Arflox/lox(known as KIC) form extremely aggressive PC tumors that result in a median survival of approximately 8 weeks [9]; PC mouse models that harbor KrasLSL-G12D/+,Dpc4flox/flox and p48-Cre (known as KDD) form MCN early on and later develop aggressive, local invasive and widely metastatic PC characterized by a survival period of 8 months [10].